PTCH1

Predictive

Supports Sensitivity Response

submitted

EID11608

In a phase 2 trial (NCT01327053), the SMO inhibitor sonidegib was tested in patients with metastatic or locally advanced basal cell carcinoma (BCC) who had not previously received a hedgehog pathway i… (full text at CIViC)

PMID 28846163 · Lear et al., 2018 · Open in CIViC

Predictive

Supports Sensitivity Response

submitted

EID11607

In a phase 2 trial (NCT00833417) the SMO inhibitor vismodegib was tested in patients (21-101 years old) with metastatic or locally advanced basal cell carcinoma at a dose of 150 mg daily. Of note, b… (full text at CIViC)

PMID 22670903 · Sekulic et al., 2012 · Open in CIViC

PTCH1 Mutation2
Sonidegib	MedulloblastomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	4	accepted	EID748 133 sonic-hedghog driven medulloblastomas were sequenced for alterations (WGS or WES). 60 cases exhibited PTCH1 mutations, most of which were likely loss-of-function (spread across the gene and of typ… (full text at CIViC) PMID 24651015 · Kool et al., 2014 · Open in CIViC	civic
Vismodegib	Malignant NeoplasmALIAS	Predictive	B	Supports Sensitivity Response	1	accepted	EID5978 The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Twenty-one p… (full text at CIViC) PMID 29320312 · Hainsworth et al., 2018 · Open in CIViC	civic

PTCH1 Mutation2

Sonidegib

MedulloblastomaCURATED_BROADER

Predictive

Supports Sensitivity Response

accepted

EID748

133 sonic-hedghog driven medulloblastomas were sequenced for alterations (WGS or WES). 60 cases exhibited PTCH1 mutations, most of which were likely loss-of-function (spread across the gene and of typ… (full text at CIViC)

PMID 24651015 · Kool et al., 2014 · Open in CIViC

Malignant NeoplasmALIAS

Predictive

Supports Sensitivity Response

accepted

EID5978

The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Twenty-one p… (full text at CIViC)

PMID 29320312 · Hainsworth et al., 2018 · Open in CIViC

PTCH1 Q17X1
Vismodegib	Basal Cell Carcinoma	Predictive	C	Supports Sensitivity Response	—	submitted	EID4684 In a basal cell carcinoma patient harboring a PTCH1 Q84* nonsense mutation, a complete response to vismodegib monotherapy was reported at 5 months of treatment. PMID 25306392 · Pricl et al., 2015 · Open in CIViC	civic

PTCH1 Q17X1

Predictive

Supports Sensitivity Response

—

submitted

EID4684

In a basal cell carcinoma patient harboring a PTCH1 Q84* nonsense mutation, a complete response to vismodegib monotherapy was reported at 5 months of treatment.

PMID 25306392 · Pricl et al., 2015 · Open in CIViC

PTCH1 Q787X1
Vismodegib	Basal Cell Carcinoma	Predictive	C	Supports Sensitivity Response	—	submitted	EID4683 In a phase 1 study (NCT00607724), an advanced, chemotherapy-refractory basal cell carcinoma patient harboring a PTCH1 Q938* nonsense mutation was associated with a partial response to vismodegib monot… (full text at CIViC) PMID 19726763 · Von Hoff et al., 2009 · Open in CIViC	civic

PTCH1 Q787X1

Predictive

Supports Sensitivity Response

—

submitted

EID4683

In a phase 1 study (NCT00607724), an advanced, chemotherapy-refractory basal cell carcinoma patient harboring a PTCH1 Q938* nonsense mutation was associated with a partial response to vismodegib monot… (full text at CIViC)

PMID 19726763 · Von Hoff et al., 2009 · Open in CIViC

PTCH1 W170X1
Vismodegib	Basal Cell Carcinoma	Predictive	C	Supports Sensitivity Response	—	submitted	EID4681 In a phase 1 study (NCT00607724), an advanced, chemotherapy-refractory basal cell carcinoma patient harboring a PTCH1 W236* nonsense mutation was associated with a partial response to vismodegib monot… (full text at CIViC) PMID 19726763 · Von Hoff et al., 2009 · Open in CIViC	civic

PTCH1 W170X1

Predictive

Supports Sensitivity Response

—

submitted

EID4681

In a phase 1 study (NCT00607724), an advanced, chemotherapy-refractory basal cell carcinoma patient harboring a PTCH1 W236* nonsense mutation was associated with a partial response to vismodegib monot… (full text at CIViC)

PMID 19726763 · Von Hoff et al., 2009 · Open in CIViC

PTCH1 W712X1
Vismodegib	Basal Cell Carcinoma	Predictive	C	Supports Sensitivity Response	—	submitted	EID4682 In a phase 1 study (NCT00607724), an advanced, chemotherapy-refractory basal cell carcinoma patient harboring a PTCH1 W863* nonsense mutation, was associated with a partial response to vismodegib mono… (full text at CIViC) PMID 19726763 · Von Hoff et al., 2009 · Open in CIViC	civic

PTCH1 W712X1

Predictive

Supports Sensitivity Response

—

submitted

EID4682

In a phase 1 study (NCT00607724), an advanced, chemotherapy-refractory basal cell carcinoma patient harboring a PTCH1 W863* nonsense mutation, was associated with a partial response to vismodegib mono… (full text at CIViC)

PMID 19726763 · Von Hoff et al., 2009 · Open in CIViC